Most Read

Under the agreement, Quotient will receive $20m upfront and could also earn up to $2.2bn through regulatory, development, and commercial milestone payments. Quotient’s somatic genomics approach analyses naturally

This collaboration is also aimed at expediting early-phase clinical trials and delivering new therapies to patients. It will leverage both organisations’ expertise to advance healthcare innovation. Each partner

The agreement grants Sanofi worldwide rights to KT501, which is under evaluation in a first-in-human clinical trial for rheumatoid arthritis, focusing on tolerability, safety, pharmacodynamics, and pharmacokinetics. Under

This approval covers adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), with or without papillary tumours. The authorisation follows a review

The FDA has approved Opdivo, along with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and paediatric patients aged 12 years and above who have not previously been treated

Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones to acquire Synnovation Therapeutics’ wholly owned subsidiary Pikavation Therapeutics, which holds SNV4818 and related

The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-deficient genetic obesity, glucocerebrosidase 1 (GBA1)-driven Parkinson’s disease, and Alpha-1 antitrypsin deficiency. The financing was co-led by Dimension and OrbiMed,

The company also secured an exclusive global licence for the development and commercialisation of AP306 with Alebund Pharmaceuticals, excluding Greater China. The funding will support the global development

This CRL stated that the application lacks substantial evidence of efficacy from adequate and well-controlled clinical investigations under the proposed conditions of use. The FDA noted inconsistencies in